We present a rare case of a patient with anaplastic thyroid carcinoma (ATC) who survived for 87 months after surgery. The patient was a 71-year-old man who presented with a painful enlarged mass in the right side of his neck that rapidly enlarged over 2 months. He was diagnosed with T4a, stage IVA ATC with no distant metastasis and underwent total thyroidectomy with modified neck dissection.
Introduction
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignant thyroid tumor, and accounts for <2% of all thyroid malignancies 1, 2 . The prognosis is poor, with a mortality rate of >90% and a mean survival of 6 months after diagnosis 2, 3 . Although ATC has diverse histopathological features, to date, none have been found to have prognostic significance 2 . Most existing knowledge about ATC is derived from single-institution studies with a limited number of patients and short-term follow-up.
To obtain further insight into this disease, the ATC Re- Patients were assigned a PI score of 1 to 4 6 . In their study, patients with PI=1 experienced a 62% survival rate at 6 months, whereas no patients with PI=3 survived longer than 6 months and all patients with PI=4 died within 3 months. A study by Sugitani et al. 6 confirmed the results of the ATCCJ and validated the ATC classification as a prognostic index. The authors recommended attempting multimodal treatment for patients with PI! 1, while avoiding aggressive treatment to maintain quality of life for patients with PI" 3 4 6 .
Here we report a rare case of a patient with ATC pT4a, pN1b, M0, stage IVA, PI=1, who survived for 87 months after surgery.
Case Report
A 71-year-old man was referred to our hospital with a chief complaint of a rapid and painful right-sided neck enlargement. A palpable, hard, unmovable tumor was observed in the right side of his neck, along with a swollen, palpable, movable lymph node. Cervical enhanced computer tomography (CT) revealed a calcified tumor with internal heterogeneity, 4.6 3.6 cm in size, that was continuous with the upper pole of the right thyroid lobe, as well as enlargement (2.3 1.9 cm) of the right cervical lymph node; no obvious infiltration was seen ( Fig. 1) . No distant metastasis was observed. The leukocyte count was 5,400/mm 3 , with no other blood cell count abnor- month later, the day before surgery, showed that the right thyroid lobe tumor and the right cervical lymph node had each increased in size by >30% to 6.2 3.2 cm and 3.4 2.3 cm, respectively (Fig. 2) . The clinical diagnosis was ATC, cT4a, cN1b, M0, stage IVA, PI=0. However, these findings did not rule out surgery. Total thyroidectomy and central and right lateral cervical lymph node dissection were performed. Histopathological findings by hematoxylin & eosin (H&E) staining showed that the tumor consisted of 70% ATC components and 30% papillary thyroid carcinoma (PTC) components ( Fig. 3, 4) . The sarcoma components, which accounted for most of the tumor, were strongly positive for CD68 and vimentin, partially positive for S-100, and negative for Tg, α-SMA, desmin, CD20, CD79a, CD3, CD45RO, CD30, and CD5. The sarcoma component stained strongly positive for CD68 and vimentin, partially positive for S-100, and negative for Tg, α-SMA, desmin, CD20, CD79a, CD3, CD45RO, CD30, and CD5. The MIB-1 labeling index showed a somewhat lower value of 30%. The tumor showed malignant fibrous histiocytoma-like features but was EMA-negative and was ultimately diagnosed as anaplastic thyroid carcinoma. 5 External beam radiation therapy of 40 Gy was performed on the neck just after surgery. A marked rise in TgAb was observed 24 months after surgery, so an additional 50 mCi of radioactive iodine (RAI) was administered, and the TgAb subsequently decreased. The TgAb increased again 46 months after surgery, and 120 mCi of RAI was administered. After RAI therapy, the Tg level did not change (average, 18.5 ng/mL), but the TgAb level decreased from 500 to 52 ng/mL. Although no currently established treatment strategies exist for ATC and it is associated with a very poor prognosis, some cases in which radical cure (i.e., surgical removal) leads to improvement in prognosis have been reported 13 , and surgical respectability has been indicated as an independent prognostic factor 14 . Furthermore, Onoda et al. reported the feasibility and objective outcomes of chemotherapy (weekly paclitaxel) for patients with ATC 15, 16 .
In the present case, bone metastasis occurred after a disease-free survival period of 84 months. The patient received Lenvatinib but died from a decline in his general condition 3 months later. Although adjuvant chemotherapy was not administered, it was considered as an option. We suggest that surgical treatment is effective for stage IVA ATC, but an effective adjuvant therapy is necessary to achieve long-term disease-free survival.
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